Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Nucana ( (NCNA) ) is now available.
NuCana reported unaudited first-quarter 2026 results on May 14, 2026, showing a widened operating loss of £4.4 million versus £2.9 million a year earlier, driven mainly by higher research and development and administrative expenses. The company ended March 31, 2026 with £21.5 million in cash and cash equivalents, down from £24.3 million at year-end 2025, leaving total equity at £22.4 million and underscoring its ongoing cash burn and reliance on existing capital resources while it advances its pipeline.
Despite the larger quarterly loss, NuCana benefited from increased finance income and a tax credit that partially offset operating expenses, resulting in a net loss of £3.9 million compared with £2.5 million in the prior-year quarter. The modest decline in total assets to £27.6 million from £29.8 million highlights continued spending but also indicates the company still has a limited runway to support operations and development activities, a key consideration for investors tracking future funding needs.
Spark’s Take on NCNA Stock
According to Spark, TipRanks’ AI Analyst, NCNA is a Neutral.
The score is primarily held down by weak financial performance (pre-revenue losses and ongoing cash burn) and a negative P/E. Technicals are mixed—some near-term strength above the 20-day average, but negative MACD and price well below longer-term moving averages keep the overall score below average.
To see Spark’s full report on NCNA stock, click here.
More about Nucana
NuCana plc is a U.K.-based biopharmaceutical company focused on developing oncology treatments, with operations funded primarily through equity capital rather than product revenues. The company remains in a clinical-stage development phase, as reflected by continued research and development spending and the absence of commercial sales in its reported financials.
Average Trading Volume: 39,997
Technical Sentiment Signal: Sell
Current Market Cap: $7.74M
For a thorough assessment of NCNA stock, go to TipRanks’ Stock Analysis page.